Is Egrifta (Tesamorelin) Legal in Texas? How to Access It Legally
HealthRX.com
Egrifta is FDA-approved; Texas access rules are separate
Key numbers
- 1.4 mgEgrifta SV dose, given once daily by injection into the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 11.6 mgEgrifta WR vial size; one vial supplies seven daily dosesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 2 mgDaily dose used in pivotal trials, from the original 1 mg/vial productSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug, application BLA 022505, first approved November 10, 2010 [1]
- Current products / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, both once-daily subcutaneous injections [2][3]
- Approved use / Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
- Approved doses / 1.4 mg daily (SV) or 1.28 mg daily (WR); the two are not substitutable [2][3]
- Not approved for / Weight loss management; the label describes a weight-neutral effect [2]
- Compounding / Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing [4][5]
What the FDA approval covers
Tesamorelin acetate was first approved on November 10, 2010, under application BLA 022505 [1]. The two products described by the current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial; both labels are dated July 29, 2026 [2][3]. FDA's database lists the original 1 mg and 2 mg vials as prescription products [1].
The approved use is narrow: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3]. The label lists limitations: long-term cardiovascular safety has not been established, the risk and benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue, and the drug is not indicated for weight loss management because its effect on weight is neutral [2]. The label also says there are no data that it improves adherence to antiretroviral therapy [2]. Use in people without HIV lipodystrophy is outside the label.
Questions worth asking
Doses on the two current labels
The Egrifta SV label gives a dose of 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously once daily into the abdomen, rotating sites [2]. The Egrifta WR label gives a dose of 1.28 mg (0.16 mL of the reconstituted 8 mg/mL solution) once daily; one reconstituted 11.6 mg vial supplies seven daily doses [3]. The WR label states that the two products are not substitutable [3]. The 2 mg daily dose used in the pivotal trials belongs to the original 1 mg/vial product; FDA accepted the 1.4 mg SV dose because its exposure is similar [2].
Label contraindications and monitoring
The labels list these contraindications: disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. The labels also call for monitoring IGF-1 and glucose during treatment [2][3].
Compounded tesamorelin
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [4][5]. Tesamorelin does not appear on FDA's page of bulk substances that may present significant safety risks when compounded [8]. It appears in no category of FDA's list for state-licensed pharmacies and physicians or of its list for outsourcing facilities, so FDA has made no category-based statement about compounding it [9][10]. It is not one of the six peptides named in the HHS draft enforcement-discretion policy for compounding filed October 28, 2026 [4][5]. Tesamorelin is already a component of an FDA-approved drug [1].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Texas?
Can tesamorelin be compounded?
What dose is approved?
Is tesamorelin approved for weight loss?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can you purchase tesamorelin online?
The federal sources used here do not address online purchase, telehealth or dispensing rules, so this is not established by them. FDA's database lists the original 1 mg and 2 mg vials as prescription products, and the approved use is limited to HIV-infected adults with lipodystrophy.
Can anyone take tesamorelin peptide?
The FDA-approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Use in people without HIV lipodystrophy is outside the label. The labels also list contraindications, including pregnancy, active malignancy and disruption of the hypothalamic-pituitary axis.
How do I get a prescription for tesamorelin?
The federal sources used here do not describe how to obtain a prescription for tesamorelin. They do establish that Egrifta is an FDA-approved prescription drug, and that Texas prescribing and dispensing rules are not covered by those sources.
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.